麦澜德(688273) - 2024 Q4 - 年度业绩

Financial Performance - Total operating revenue for 2024 reached 422.68 million yuan, a year-on-year increase of 24.02%[4] - Operating profit was 112.79 million yuan, reflecting a growth of 10.06% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was 102.17 million yuan, up 13.75% year-on-year[4] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 90.44 million yuan, an increase of 26.42%[4] - Basic earnings per share were 1.0369 yuan, representing a 15.44% increase from the previous year[4] - The weighted average return on net assets increased by 1.01 percentage points to 7.64%[4] Assets and Equity - Total assets at the end of the reporting period amounted to 1,547.64 million yuan, a growth of 0.89% from the beginning of the period[4] - Equity attributable to shareholders of the parent company decreased by 2.45% to 1,312.79 million yuan[4] Business Strategy - The company strengthened brand building and optimized sales channels, leading to rapid growth in sales of reproductive rehabilitation products and consumables[6] Cautionary Note - The company warns that the financial data presented are preliminary and subject to final audit, urging investors to be aware of investment risks[7]